Remus Pharmaceuticals Ltd (REMP)

2,024.00 +105.45 (+5.50%)
Real-time Data INR Disclaimer

REMP Financial Summary

Remus Pharmaceuticals Limited reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was INR 2,125 million. Revenue was INR 2,178.99 million. Net income was INR 215.37 million. Basic earnings per share from continuing operations was INR 152.01. Diluted earnings per share from continuing operations was INR 152.01.
TTM
Trailing Twelve Months
MRQ
Most Recent Quarter
REMP
Gross margin TTM 22.67%
Operating margin TTM 12.67%
Net Profit margin TTM 10.14%
Return on Investment TTM 0%
Total Revenue
Net Income
Title
Mar 31, 2023
Total Revenue
Gross Profit 66.18
Operating Income
Net Income 20.64
Clear All
0Selected
Please try another search
REMP
Quick Ratio MRQ 0
Current Ratio MRQ -
LT Debt to Equity MRQ 0%
Total Debt to Equity MRQ 0%
Total Assets
Total Liabilities
Title
Mar 31, 2023
Total Assets
Total Liabilities 155.26
Total Equity 191.36
Clear All
0Selected
Please try another search
REMP
Cash Flow/Share TTM 6.11
Revenue/Share TTM 360.66
Operating Cash Flow -0.14%
Cash
Net Change in Cash
Title
Mar 31, 2023
Cash From Operating Activities -0.12
Cash From Investing Activities -6.84
Cash From Financing Activities -16.29
Net Change in Cash -23.25
Clear All
0Selected
Please try another search

* In Millions of INR (except for per share items)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles